3-(N-(4-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butyl)sulfamoyl)benzoic acid

ID: ALA3322511

PubChem CID: 118710195

Max Phase: Preclinical

Molecular Formula: C23H20N2O6S

Molecular Weight: 452.49

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)c1cccc(S(=O)(=O)NCCCCN2C(=O)c3cccc4cccc(c34)C2=O)c1

Standard InChI:  InChI=1S/C23H20N2O6S/c26-21-18-10-4-6-15-7-5-11-19(20(15)18)22(27)25(21)13-2-1-12-24-32(30,31)17-9-3-8-16(14-17)23(28)29/h3-11,14,24H,1-2,12-13H2,(H,28,29)

Standard InChI Key:  KUNDLECGYTVOQE-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    3.0152   -5.8547    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.4370   -5.1548    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.6200   -5.1394    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.1419   -5.5724    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4506   -4.3373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1647   -3.9424    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1759   -3.1260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4732   -2.7077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7577   -3.1107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7500   -3.9257    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1328   -6.3895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3399  -10.4790    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3388  -11.2985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0468  -11.7075    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7544  -11.2944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4630  -11.7015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1712  -11.2907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1665  -10.4685    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7537  -10.4754    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4575  -10.0666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4544   -9.2546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7482   -8.8504    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0438   -9.2641    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0503  -10.0748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1606   -8.8434    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3329   -8.8610    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.7437   -8.0332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4491   -7.6207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4446   -6.8035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0512   -2.6930    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0594   -1.8759    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.3394   -3.0945    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  2  1  0
  2  5  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
  4 11  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 24 12  2  0
 19 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 20  1  0
 19 20  2  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 19  1  0
 21 25  2  0
 23 26  2  0
 22 27  1  0
 27 28  1  0
 28 29  1  0
 29 11  1  0
 30 31  1  0
 30 32  2  0
  9 30  1  0
M  END

Alternative Forms

  1. Parent:

    ALA3322511

    ---

Associated Targets(Human)

LPAR2 Tchem Lysophosphatidic acid receptor Edg-4 (418 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LPAR1 Tchem Lysophosphatidic acid receptor Edg-2 (779 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LPAR3 Tchem Lysophosphatidic acid receptor Edg-7 (471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LPAR5 Tchem Lysophosphatidic acid receptor 5 (213 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Lpar4 Lysophosphatidic acid receptor 4 (31 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MEF (1005 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHO (4503 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
B103 cell line (42 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Biocomponents

Calculated Properties

Molecular Weight: 452.49Molecular Weight (Monoisotopic): 452.1042AlogP: 2.89#Rotatable Bonds: 8
Polar Surface Area: 120.85Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 3.75CX Basic pKa: CX LogP: 2.77CX LogD: -0.51
Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.40Np Likeness Score: -1.14

References

1. Patil R, Fells JI, Szabó E, Lim KG, Norman DD, Balogh A, Patil S, Strobos J, Miller DD, Tigyi GJ..  (2014)  Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.,  57  (16): [PMID:25100502] [10.1021/jm5007116]
2. Bandoh, K K and 5 more authors.  2000-07-28  Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.  [PMID:10922489]
3. Kano, Kuniyuki K, Arima, Naoaki N, Ohgami, Mitsuru M and Aoki, Junken J.  2008  LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.  [PMID:18781939]
4. Williams, Jesica R JR and 8 more authors.  2009-06-19  Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.  [PMID:19366702]
5. Zhang, Honglu H and 10 more authors.  2009-07-01  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.  [PMID:19509223]
6. Fells, James I; Tsukahara, Ryoko; Liu, Jianxiong; Tigyi, Gabor and Parrill, Abby L.  2009-11-01  Structure-based drug design identifies novel LPA3 antagonists.  [PMID:19800804]
7. Banerjee, Souvik S and 7 more authors.  2017-02-23  Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.  [PMID:28112925]

Source